<unk> , sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains<unk> , lamivudine, and<unk>  disoproxil. It is taken by mouth. In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.
Doravirine/lamivudine/tenofovir
Lamivudine/tenofovir
Abacavir/lamivudine
Lamivudine/nevirapine/zidovudine
Abacavir/lamivudine/zidovudine
Lamivudine/zidovudine
Lamivudine/nevirapine/stavudine
Efavirenz/lamivudine/tenofovir